Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. (Q37716013)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20307221 AND SRC:MED&resulttype=core&format=json

28 January 2020

review article

1 reference

title

Olopatadine: a drug for allergic conjunctivitis targeting the mast cell (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20307221 AND SRC:MED&resulttype=core&format=json

28 January 2020

main subject

mast cell

0 references

allergic conjunctivitis

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20307221 AND SRC:MED&resulttype=core&format=json

28 January 2020

1

Andrea Leonardi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20307221 AND SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

English

0 references

publication date

1 April 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20307221 AND SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

28 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20307221 AND SRC:MED&resulttype=core&format=json

28 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20307221 AND SRC:MED&resulttype=core&format=json

28 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20307221 AND SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

969-981

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20307221 AND SRC:MED&resulttype=core&format=json

Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Allergy and allergic diseases. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Allergic conjunctivitis: update on pathophysiology and prospects for future treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Allergic rhinitis: selective comparisons of the pharmaceutical options for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Mast cells as "tunable" effector and immunoregulatory cells: recent advances.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

The ins and outs of IgE-dependent mast-cell exocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Mast-cell responses to pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Molecular regulation of mast cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Mechanisms of Antihistamines and Mast Cell Stabilizers in Ocular Allergic Inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Mast cell numbers and staining characteristics in the normal and allergic human conjunctiva

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Histamine receptors and the conjunctiva

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Human conjunctival mast cell responses in vitro to various secretagogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Macrophage inflammatory protein-1alpha as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Role of chemokines in vernal keratoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Neural integration and allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Emerging drugs for ocular allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Allergic subjects express intercellular adhesion molecule--1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Comparative Effects of Topical Ocular Anti-Allergy Drugs on Human Conjunctival Mast Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Effects of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I). Elucidation of the mechanism for histamine release inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Interactions of olopatadine and selected antihistamines with model and natural membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

The promotion of eosinophil degranulation and adhesion to conjunctival epithelial cells by IgE-activated conjunctival mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Inhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 expression in eosinophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2 -dependent protein kinase C, Raf/MEK/ERK and IKK/I kappa B/NF-kappa B signal cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Anti-allergic drug olopatadine suppresses murine contact hypersensitivity and downmodulates antigen-presenting ability of epidermal Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

A review of olopatadine for the treatment of ocular allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Evaluation of Comfort Using Olopatadine Hydrochloride 0.1% Ophthalmic Solution in the Treatment of Allergic Conjunctivitis in Contact Lens Wearers Compared to Placebo Using the Conjunctival Allergen-Challenge Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Double-masked, randomized, parallel-group study comparing olopatadine 0.1% ophthalmic solution with cromolyn sodium 2% and levocabastine 0.05% ophthalmic preparations in children with seasonal allergic conjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Efficacy of nedocromil sodium and cromolyn sodium in an experimental model of ocular allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Effect of ketotifen and oxatomide on histamine secretion from mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Inhibition of calcium ionophore (A23187)-stimulated histamine release from rat peritoneal mast cells by azelastine: Implications for its mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

Effects of sodium cromoglycate and nedocromil sodium on histamine secretion from mast cells from various locations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003694643

10.1517/14656561003694643

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20307221 AND SRC:MED&resulttype=core&format=json

28 January 2020

1 reference